Use of Regulatory T Cells as a Cellular Therapy for Transplant Rejection/Autoimmunity | Biomedgrid
Journal: American Journal of Biomedical Science & Research (Vol.5, No. 2)Publication Date: 2019-09-10
Authors : Nick D Jones; Renad Alhamawi;
Page : 86-88
Keywords : Antigen specific Treg; Autoimmunity; GVHD; Treg; Transplantation; AJBSR;
Abstract
Foxp3+ regulatory T cells (Treg) are a crucial sub-population of T cells in the control of immunity and the maintenance of immunological tolerance aiding the prevention of autoimmunity. As such Treg have been proposed to be a candidate cell that could be used as cellular therapy to suppress unwanted immune responses. Indeed, there is an expanding literature on the potential use of Treg to induce or re-establish tolerance in both autoimmune diseases such as type I diabetes, arthritis and chronic inflammatory diseases as well as in preventing allograft rejection and graft versus host disease (GVHD). Furthermore, the finding that antigen specific Treg are superior to polyclonal Treg in a range of disease settings has raised the possibility that Treg based therapies may be refined and improved by genetic manipulation.
Other Latest Articles
- Rhabdomyolysis After Cocaine Consumption-Case Report | Biomedgrid
- PROBLEMS OF TANKS FIRE PROTECTION WITH NEW EUROPEAN FUEL
- ISSUES OF DESIGN AND PRODUCTION IMPLEMENTATION OF GAS-SENSING FIRE DETECTORS
- INDEX OF THE MATERIAL DAMAGE FROM FIRES IN RURAL TERRAIN IN RUSSIAN FEDERATION FOR 2006–2010 YEARS
- ABOUT THE CATEGORY OF GAS-GEOCHEMICAL DANGER OF BACKFILL
Last modified: 2019-10-24 17:41:43